|
US5691147A
(en)
|
1994-06-02 |
1997-11-25 |
Mitotix, Inc. |
CDK4 binding assay
|
|
US6486214B1
(en)
|
1997-09-10 |
2002-11-26 |
Rutgers, The State University Of New Jersey |
Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
|
|
HRP20020751B1
(hr)
|
2000-02-15 |
2011-01-31 |
Sugen |
Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
|
|
AU2004293026B2
(en)
|
2003-11-21 |
2012-01-19 |
Array Biopharma Inc. |
AKT protein kinase inhibitors
|
|
AU2005322085B2
(en)
|
2004-12-28 |
2012-07-19 |
Exelixis, Inc. |
[1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
|
|
RU2481336C2
(ru)
|
2006-07-06 |
2013-05-10 |
Эррэй Биофарма Инк. |
Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
|
|
UA95641C2
(xx)
|
2006-07-06 |
2011-08-25 |
Эррей Биофарма Инк. |
Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
|
|
US8648096B2
(en)
|
2006-09-15 |
2014-02-11 |
Celgene Corporation |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
|
WO2008109104A1
(en)
|
2007-03-07 |
2008-09-12 |
The Regents Of The University Of California |
Bivalent inhibitors of akt protein kinase
|
|
MX2009014013A
(es)
|
2007-07-05 |
2010-01-28 |
Array Biopharma Inc |
Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
|
|
CA2692502C
(en)
|
2007-07-05 |
2016-03-01 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
US20110172107A1
(en)
|
2008-04-30 |
2011-07-14 |
Fox Chase Cancer Center |
Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
|
|
AU2010289321A1
(en)
|
2009-09-04 |
2012-04-05 |
The Regents Of The University Of Michigan |
Compositions and methods for treatment of leukemia
|
|
SG183257A1
(en)
|
2010-02-11 |
2012-09-27 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
WO2011159685A2
(en)
|
2010-06-16 |
2011-12-22 |
The Regents Of The University Of Michigan |
Inhibition of wdr5 interaction with its binding partners and therapeutic methods
|
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
KR101316101B1
(ko)
*
|
2011-05-26 |
2013-10-11 |
연세대학교 산학협력단 |
Ｐｔｋ 6의 활성 억제용 조성물 및 이를 이용한 암 예방 및 치료용 조성물
|
|
KR102438072B1
(ko)
*
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013170147A1
(en)
|
2012-05-11 |
2013-11-14 |
Yale University |
Compounds useful for promoting protein degradation and methods using same
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
US9604930B2
(en)
|
2012-12-21 |
2017-03-28 |
Epizyme, Inc. |
Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
|
|
JP2016540811A
(ja)
*
|
2013-12-20 |
2016-12-28 |
ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ |
Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
|
|
RU2670762C2
(ru)
|
2013-12-31 |
2018-10-25 |
Хуаньчжу Фарма Ко., Лтд. |
Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
|
|
WO2015104677A1
(en)
|
2014-01-10 |
2015-07-16 |
Piramal Enterprises Limited |
Heterocyclic compounds as ezh2 inhibitors
|
|
EP4649963A3
(en)
|
2014-04-14 |
2026-05-13 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
IL325256A
(en)
|
2014-06-13 |
2026-02-01 |
Bach Biosciences Llc |
FAP-activated medical materials and related uses
|
|
AU2015301196A1
(en)
|
2014-08-04 |
2017-01-12 |
Epizyme, Inc. |
PRMT5 inhibitors and uses thereof
|
|
CA2964629A1
(en)
|
2014-11-06 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
EP3227446A1
(en)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Compositions and methods for diagnosis and treatment of prostate cancer
|
|
JP6815318B2
(ja)
*
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
WO2016106518A1
(zh)
|
2014-12-29 |
2016-07-07 |
深圳市日上光电股份有限公司 |
导线集成式照明灯箱
|
|
TWI698436B
(zh)
|
2014-12-30 |
2020-07-11 |
美商佛瑪治療公司 |
作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
|
|
WO2016115480A1
(en)
|
2015-01-16 |
2016-07-21 |
Vedantra Pharmaceuticals, Inc. |
Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
|
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
CN108137593B
(zh)
|
2015-04-21 |
2021-01-05 |
上海交通大学医学院附属瑞金医院 |
蛋白激酶抑制剂的制备和用途
|
|
EP3289074B1
(en)
|
2015-04-28 |
2023-10-04 |
Université de Strasbourg |
Clinical gene signature-based human cell culture model and uses thereof
|
|
GB201508747D0
(en)
*
|
2015-05-21 |
2015-07-01 |
Univ Edinburgh |
Compounds
|
|
CA2988414C
(en)
*
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
BR112017027951A2
(pt)
|
2015-06-22 |
2018-08-28 |
Ono Pharmaceutical Co., Ltd. |
composto inibitório de brk
|
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
CN105175284B
(zh)
|
2015-07-21 |
2017-06-16 |
中国药科大学 |
酰胺类化合物、制备方法及其医药用途
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017024317A2
(en)
*
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
AU2016315878A1
(en)
|
2015-09-03 |
2018-03-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
GB201516243D0
(en)
*
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
AU2017226005A1
(en)
|
2016-03-01 |
2018-09-06 |
Propellon Therapeutics Inc. |
Inhibitors of WDR5 protein-protein binding
|
|
US11319299B2
(en)
|
2016-03-01 |
2022-05-03 |
Propellon Therapeutics Inc. |
Substituted carboxamides as inhibitors of WDR5 protein-protein binding
|
|
WO2017185031A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN121974842A
(zh)
*
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
AR109596A1
(es)
|
2016-09-09 |
2018-12-26 |
Incyte Corp |
Compuestos pirazolopiridina y sus usos
|
|
US10160763B2
(en)
|
2016-09-13 |
2018-12-25 |
Vanderbilt University |
WDR5 inhibitors and modulators
|
|
MX2019004950A
(es)
|
2016-10-28 |
2019-09-26 |
Icahn School Med Mount Sinai |
Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
|
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
CA3045037A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
US11052091B2
(en)
*
|
2016-12-21 |
2021-07-06 |
Ono Pharmaceutical Co., Ltd. |
BRK inhibitory compound
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
IL319363A
(en)
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019113071A1
(en)
|
2017-12-05 |
2019-06-13 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating alk-mediated cancer
|
|
ES3041854T3
(en)
|
2018-01-22 |
2025-11-17 |
Bioventures Llc |
Bcl-2 proteins degraders for cancer treatment
|
|
CA3091041A1
(en)
|
2018-02-22 |
2019-08-29 |
Ichan School Of Medicine At Mount Sinai |
Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
|
|
JP2021515013A
(ja)
|
2018-03-06 |
2021-06-17 |
アイカーン スクール オブ メディスン アット マウント シナイ |
セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
|
|
CA3100211A1
(en)
|
2018-05-15 |
2019-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
|
|
JP2021527666A
(ja)
|
2018-06-21 |
2021-10-14 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
|
|
CN114423463B
(zh)
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
EP3980423A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
|
|
WO2021021904A1
(en)
|
2019-07-30 |
2021-02-04 |
The Scripps Research Institute |
Pharmacological inhibitors of the enl yeats domain
|
|
CN112552293A
(zh)
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
TWI918648B
(zh)
|
2020-05-06 |
2026-03-21 |
美商新銳思生物製藥股份有限公司 |
造血前驅細胞激酶之雙官能降解劑及其治療用途
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
US20230391765A1
(en)
|
2020-10-21 |
2023-12-07 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of enl
|
|
CN112778303A
(zh)
|
2020-12-31 |
2021-05-11 |
武汉九州钰民医药科技有限公司 |
Cdk4/6激酶抑制剂shr6390的制备方法
|
|
EP4377318A4
(en)
|
2021-07-30 |
2025-06-04 |
BeiGene, Ltd. |
PYRROLO[2,3-B PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND USE THEREOF
|